CCM plans to go into more niche areas

TheStar Thu, Feb 21, 2019 10:31am - 5 years View Original


Group managing director Leonard Ariff Abdul Shatar(pic) said biosimilar products currently contributed 22% of total revenue, and the company planned to gradually increase it to more than 25% through erythropoietin (EPO) treatment registration

Group managing director Leonard Ariff Abdul Shatar(pic) said biosimilar products currently contributed 22% of total revenue, and the company planned to gradually increase it to more than 25% through erythropoietin (EPO) treatment registration

SHAH ALAM: CCM Duopharma Biotech Bhd , which has received shareholders' nod for a name change as part of its corporate rebranding exercise, plans to enter into more niche areas with less competition in order not to be reliant on its generic drug portfolio.

Group managing director Leonard Ariff Abdul Shatar said biosimilar products currently contributed 22% of total revenue, and the company planned to gradually increase it to more than 25% through erythropoietin (EPO) treatment registration.

(Biosimilar products that are very similar but not identical to other licensed biological products, unlike generic medicines that are considered equivalents.)

...

Full Article on TheStar

The content is a snapshot from Publisher. Refer to the original content for accurate info. Contact us for any changes.






Related Stocks

2879 0.000
DPHARMA 1.200

Comments

Login to comment.